US Federal 2025-2026 Regular Session

US Federal House Bill HB7050

Introduced
1/14/26  

Caption

Homeopathic Drug Product Safety, Quality, and Transparency Act

Impact

One of the most significant implications of HB 7050 is the introduction of new safety and quality standards specifically tailored for homeopathic drug products. It states that homeopathic products must comply with standards set forth in the Homeopathic Pharmacopoeia of the United States or accredited consensus standards. The bill also permits manufacturers to petition for exemptions or alternative standards, which may ease compliance for some companies while reinforcing product safety requirements. Moreover, the act emphasizes the non-preemption of state laws concerning homeopathy practice, thereby maintaining local regulatory frameworks and allowing states to impose their own regulations in this sector.

Summary

House Bill 7050, also known as the Homeopathic Drug Product Safety, Quality, and Transparency Act, is designed to establish a regulatory framework for homeopathic drug products under the Federal Food, Drug, and Cosmetic Act. This bill aims to ensure that consumers and health care providers have access to homeopathic drugs that are safe, of high quality, and transparently labeled. The legislation reflects a recognition of the importance of homeopathy to many Americans and seeks to create a distinct regulatory pathway for these products while simultaneously allowing for federal oversight against adulterated or misbranded items.

Contention

Despite its benefits, HB 7050 has sparked discussions around the balance of regulation and consumer choice. Supporters argue that establishing clear regulations will enhance consumer safety and confidence in homeopathic products. Critics have raised concerns over potential barriers to access, insisting that overly stringent regulations could limit product availability and consumer options. Furthermore, there's a debate regarding the potential for regulatory overreach, wherein federal guidelines might conflict with state practices in homeopathy—an area historically governed by local standards and practices.

Companion Bills

No companion bills found.

Previously Filed As

US SB229

DTC Act of 2025 Drug-price Transparency for Consumers Act of 2025

US HB3789

DTC Act of 2025 Drug-price Transparency for Consumers Act of 2025

US HB8339

Drug Origin Transparency Act of 2026

US HB1143

Menstrual Product Transparency and Safety Act of 2026; enact

US HB06598

An Act Expanding The Scope Of Practice Of Homeopathic Physicians.

US SB2766

Consumer Safety Technology Act Digital Taxonomy Act Blockchain Innovation Act AI for Consumer Product Safety Act

US HB3847

Student-athlete Protections and Opportunities through Rights, Transparency, and Safety Act

US HB1770

AI for Consumer Product Safety Act Digital Taxonomy Act Blockchain Innovation Act

US SB365

"Georgia Meat and Organic Produce Transparency and Safety Act"; enact

US SB1302

Increasing Transparency in Generic Drug Applications Act

Similar Bills

NV SB397

Makes various changes relating to alternative medicine. (BDR 54-117)

FL S1524

Practice of Chiropractic Medicine

NJ A3397

Expands scope of practice for licensed acupuncturists.

FL H0439

Practice of Chiropractic Medicine

NJ S2973

Expands services that licensed acupuncturists may provide.

CT HB06598

An Act Expanding The Scope Of Practice Of Homeopathic Physicians.

AZ SB1235

Health profession regulatory boards; membership

NJ AJR34

Designates April 9th of each year as Dr. James Still Day in New Jersey.